

Edward M Vital

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7964900/publications.pdf>

Version: 2024-02-01

94
papers

5,145
citations

212478

28
h-index

107981

68
g-index

102
all docs

102
docs citations

102
times ranked

5379
citing authors

#	ARTICLE	IF	CITATIONS
1	Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index. <i>Rheumatology</i> , 2022, 61, 4006-4015.	0.9	14
2	Applying Early Intervention Strategies to Autoimmune Skin Diseases. Is the Window of Opportunity Preclinical? A Dermato-Rheumatology Perspective. <i>Journal of Investigative Dermatology</i> , 2022, 142, 944-950.	0.3	7
3	Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. <i>Lancet Rheumatology</i> , The, 2022, 4, e282-e292.	2.2	34
4	A glimpse into the future of systemic lupus erythematosus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210867.	1.2	14
5	Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 951-961.	0.5	38
6	A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus. <i>Rheumatology and Therapy</i> , 2022, 9, 781-802.	1.1	9
7	Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab. <i>Rheumatology</i> , 2022, 61, 4905-4909.	0.9	13
8	Early intervention in systemic lupus erythematosus: time for action to improve outcomes and health-care utilization. <i>Rheumatology Advances in Practice</i> , 2022, 6, rkab106.	0.3	2
9	P245â€fIdentifying predictors of short-term response to rituximab in extra-glandular primary Sjogrenâ€™s Syndrome. <i>Rheumatology</i> , 2022, 61, .	0.9	1
10	OA13â€fComprehensive genetic and functional analyses of Fc gamma receptors explain response to rituximab therapy for autoimmune rheumatic diseases. <i>Rheumatology</i> , 2022, 61, .	0.9	0
11	P246â€fRevision to musculoskeletal domain of BILAG-2004 index to incorporate ultrasound findings. <i>Rheumatology</i> , 2022, 61, .	0.9	0
12	Keratinocytes: From passive targets to active mediators of systemic autoimmunity. <i>Science Translational Medicine</i> , 2022, 14, eabo3961.	5.8	2
13	P241â€fEfficacy of obinutuzumab in systemic lupus erythematosus patients with secondary non response to rituximab. <i>Rheumatology</i> , 2022, 61, .	0.9	1
14	OA09â€fGene expression analysis reveals distinct ancestry-specific profiles associated with response to rituximab in SLE. <i>Rheumatology</i> , 2022, 61, .	0.9	0
15	<i>De novo</i> lupus nephritis during treatment with belimumab. <i>Rheumatology</i> , 2021, 60, 4348-4354.	0.9	14
16	TNF-Î± Regulates Human Plasmacytoid Dendritic Cells by Suppressing IFN-Î± Production and Enhancing T Cell Activation. <i>Journal of Immunology</i> , 2021, 206, 785-796.	0.4	33
17	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.5	37
18	Investigation of type I interferon responses in ANCA-associated vasculitis. <i>Scientific Reports</i> , 2021, 11, 8272.	1.6	6

#	ARTICLE	IF	CITATIONS
19	Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study. <i>Rheumatology</i> , 2021, 60, 5194-5204.	0.9	16
20	P169â€fA validated two-score system for interferon is a predictor of response to rituximab in SLE. <i>Rheumatology</i> , 2021, 60, .	0.9	0
21	O19â€fEasy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004. <i>Rheumatology</i> , 2021, 60, .	0.9	0
22	Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination. <i>Vaccines</i> , 2021, 9, 435.	2.1	284
23	Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. <i>Lupus</i> , 2021, 30, 1254-1263.	0.8	36
24	A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis. <i>Frontiers in Immunology</i> , 2021, 12, 803175.	2.2	8
25	Interleukin-7: a potential factor supporting B-cell maturation in the rheumatoid arthritis synovium. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 253-262.	0.4	0
26	Interleukin-7: a potential factor supporting B-cell maturation in the rheumatoid arthritis synovium. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 253-262.	0.4	1
27	Assessment of responsiveness of the musculoskeletal component of SLE-DAS in an independent cohort. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e51-e51.	0.5	3
28	B Cell Tetherin: A Flow Cytometric Cellâ€fSpecific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020, 72, 769-779.	2.9	16
29	O12â€fEffect of rituximab on RA-associated bronchiectasis and comparison of 5-year respiratory survival with TNFi. <i>Rheumatology</i> , 2020, 59, .	0.9	0
30	O34â€fPredicting autoimmune connective tissue diseases: three year follow up of an at-risk cohort identifies late progression and predicts need for therapy. <i>Rheumatology</i> , 2020, 59, .	0.9	0
31	Lessons for rituximab therapy in patients with rheumatoid arthritis. <i>Lancet Rheumatology, The</i> , 2020, 2, e497-e509.	2.2	20
32	Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. <i>Nature Communications</i> , 2020, 11, 6149.	5.8	71
33	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.5	35
34	Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab. <i>Frontiers in Medicine</i> , 2020, 7, 498.	1.2	15
35	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 1231-1233.	2.9	0
36	Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis. <i>Rheumatology</i> , 2020, 59, 2838-2846.	0.9	5

#	ARTICLE	IF	CITATIONS
37	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.5	759
38	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	2.9	1,098
39	Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. <i>Lancet Rheumatology</i> , The, 2019, 1, e208-e219.	2.2	250
40	Effectiveness and safety of switch to rituximab biosimilar with rheumatoid arthritis. a single centre experience. <i>Rheumatology</i> , 2019, 58, .	0.9	0
41	Non-invasive Approaches for the Diagnosis of Autoimmune/Autoinflammatory Skin Diseases—A Focus on Psoriasis and Lupus erythematosus. <i>Frontiers in Immunology</i> , 2019, 10, 1931.	2.2	20
42	Validity and sensitivity to change of laser Doppler imaging as a novel objective outcome measure for cutaneous lupus erythematosus. <i>Lupus</i> , 2019, 28, 1320-1328.	0.8	2
43	Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. <i>Arthritis and Rheumatology</i> , 2019, 71, 1812-1823.	2.9	89
44	Baseline characteristics of patients with lupus nephritis requiring rituximab therapy: results from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR). <i>Rheumatology</i> , 2019, 58, .	0.9	0
45	Michael Mason winner. <i>Rheumatology</i> , 2019, 58, .	0.9	0
46	Work participation, mobility and foot symptoms in people with systemic lupus erythematosus: findings of a UK national survey. <i>Journal of Foot and Ankle Research</i> , 2019, 12, 26.	0.7	10
47	Targeted therapy using intradermal injection of etanercept for remission induction in discoid lupus erythematosus (TARGET-DLE): results from a proof-of-concept phase II trial. <i>Rheumatology</i> , 2019, 58, .	0.9	0
48	OP0021...PREDICTING SEVERE INFECTION IN REPEAT CYCLES OF RITUXIMAB AND EFFECTS OF HYPOGAMMAGLOBULINAEMIA FOR THE TREATMENT OF RHEUMATIC AND MUSCULOSKELETAL DISEASES. , 2019, , .		0
49	Plucked hair follicles from patients with chronic discoid lupus erythematosus show a disease-specific molecular signature. <i>Lupus Science and Medicine</i> , 2019, 6, e000328.	1.1	14
50	Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 1353-1360.	0.9	14
51	Resistant type II cryoglobulinaemic vasculitis successfully treated with bortezomib in a patient with SLE. <i>BMJ Case Reports</i> , 2019, 12, e226083.	0.2	1
52	Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 304-312.	0.9	28
53	A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features. <i>Scientific Reports</i> , 2018, 8, 5793.	1.6	70
54	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. <i>Rheumatology</i> , 2018, 57, 470-479.	0.9	73

#	ARTICLE	IF	CITATIONS
55	Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1432-1439.	0.5	79
56	Development and Validation of the OMERACT Rheumatoid Arthritis Magnetic Resonance Tenosynovitis Scoring System in a Multireader Exercise. <i>Journal of Rheumatology</i> , 2017, 44, 1688-1693.	1.0	23
57	Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre. <i>Rheumatology</i> , 2017, 56, 1348-1357.	0.9	153
58	The prevalence of self-reported lower limb and foot health problems experienced by participants with systemic lupus erythematosus: Results of a UK national survey. <i>Lupus</i> , 2017, 26, 410-416.	0.8	22
59	Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. <i>Rheumatology</i> , 2017, 56, kew431.	0.9	89
60	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. <i>Rheumatology</i> , 2017, 56, 1041-1043.	0.9	2
61	Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1829-1836.	0.5	90
62	08.46...Alterations in peripheral blood b-cell subsets following conventional and tnf-inhibitor therapies in patients with early, treatment-naïve rheumatoid arthritis. , 2017, , .		0
63	Musculoskeletal manifestations of systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2017, 29, 486-492.	2.0	29
64	Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?. <i>Arthritis Research and Therapy</i> , 2017, 19, 239.	1.6	38
65	Chylous ascites in a patient with an overlap syndrome: a surprising response to rituximab. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-222339.	0.2	3
66	The initiation of autoimmunity at epithelial surfaces: a focus on rheumatoid arthritis and systemic lupus erythematosus. <i>Discovery Medicine</i> , 2017, 24, 191-200.	0.5	13
67	The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review. <i>Rheumatology</i> , 2016, 55, kev343.	0.9	25
68	Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 294.	1.6	27
69	Network Analysis Identifies Proinflammatory Plasma Cell Polarization for Secretion of ISG15 in Human Autoimmunity. <i>Journal of Immunology</i> , 2016, 197, 1447-1459.	0.4	52
70	295. Flow-Based Cell-Specific Interferon Signature as a Biomarker in Systemic Lupus Erythematosus. <i>Rheumatology</i> , 2015, , .	0.9	0
71	Brief Report: Responses to Rituximab Suggest B Cell-Independent Inflammation in Cutaneous Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2015, 67, 1586-1591.	2.9	82
72	Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1734-1738.	0.5	33

#	ARTICLE	IF	CITATIONS
73	B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use. Current Rheumatology Reports, 2015, 17, 65.	2.1	16
74	IFN γ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism. Journal of Investigative Dermatology, 2015, 135, 2935-2943.	0.3	20
75	An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. Annals of the Rheumatic Diseases, 2015, 74, 1195-1201.	0.5	48
76	Law of the Vital Few: Choosing Variables of Disease Activity in Rheumatoid Arthritis. Journal of Rheumatology, 2014, 41, 2097-2098.	1.0	0
77	Choosing the Right Rituximab Dose for the Right Patient: Comment on the Article by Bredemeier et al. Arthritis Care and Research, 2014, 66, 1591-1593.	1.5	1
78	An immunological biomarker to predict MTX response in early RA. Annals of the Rheumatic Diseases, 2014, 73, 2047-2053.	0.5	51
79	Biologics in systemic lupus erythematosus: current options and future perspectives. British Journal of Hospital Medicine (London, England: 2005), 2014, 75, 440-447.	0.2	7
80	Rituximab biosimilars. Expert Opinion on Biological Therapy, 2013, 13, 1049-1062.	1.4	34
81	FRI0227â€¦Acpa fine specificity is associated with increased plasmablast numbers and worse clinical response to rituximab in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, A450.1-A450.	0.5	1
82	OP0045â€¦Synovial B Cell Status Determines Intensity of Rituximab Therapy Required in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A64.3-A65.	0.5	0
83	Concomitant cyclophosphamide and oral immunosuppressants with rituximab for systemic lupus erythematosus. Rheumatology, 2012, 51, 1131-1132.	0.9	6
84	Reduced-dose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletion. Arthritis and Rheumatism, 2011, 63, 603-608.	6.7	72
85	B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis and Rheumatism, 2011, 63, 3038-3047.	6.7	191
86	Management of nonresponse to rituximab in rheumatoid arthritis: Predictors and outcome of reâ€¢treatment. Arthritis and Rheumatism, 2010, 62, 1273-1279.	6.7	112
87	Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis and Rheumatism, 2008, 58, 2993-2999.	6.7	187
88	The development of targeted therapies in rheumatoid arthritis. Journal of Autoimmunity, 2008, 31, 219-227.	3.0	37
89	Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Annals of the Rheumatic Diseases, 2008, 67, 1541-1544.	0.5	381
90	Abatacept. Drugs of Today, 2006, 42, 87.	0.7	4

#	ARTICLE	IF	CITATIONS
91	Abatacept in the treatment of rheumatoid arthritis. Therapeutics and Clinical Risk Management, 2006, 2, 365-375.	0.9	36
92	061.â€fRituximab-Associated Neutropaenia: Safety of Retreatment Rituximab Therapy. Rheumatology, 0, , .	0.9	1
93	116â€fResults of a National Foot Health Survey of Patients with Systemic Lupus Erythematosus. Rheumatology, 0, , .	0.9	0
94	Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome. ACR Open Rheumatology, 0, , .	0.9	2